RIMSTAR®

DRUG2 trials

Sponsors

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Conditions

Bacilliferous pulmonary tuberculosisTUBERCULOSIS

Phase 2

RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).

CompletedCTIS2023-509075-17-00

Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaBacilliferous pulmonary tuberculosis

Start: 2024-01-17End: 2025-04-10Target: 120Updated: 2025-06-27

Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis

Not yet recruitingCTIS2024-519983-42-00

Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaTUBERCULOSIS

Target: 50Updated: 2025-02-04

Related Papers

Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol.

2025-12-07